Quick answer: An above-the-line credit is R&D tax relief recognised as taxable income in a company's profit and loss account, above the operating-profit line, rather than as a straight reduction in corporation tax. From 1 April 2024 the UK's merged R&D scheme delivers relief this way at 20% (27% under ERIS), which lifts reported EBITDA.
What is an above-the-line credit?
An above-the-line credit, also called an expenditure credit, is a form of R&D tax relief that appears as taxable income in the company's profit and loss account, above the operating profit line. The pre-tax credit is recognised as other operating income, and the related corporation tax charge on it is reflected in the tax line. This contrasts with the former SME enhanced deduction, which reduced taxable profit only. From 1 April 2024 the UK's merged R&D scheme is delivered entirely as an above-the-line credit.
How does HMRC define the above-the-line credit?
HMRC's guidance on the above-the-line mechanism is set out at CIRD89750 and across the RDEC sections CIRD89700 to CIRD89850. The accounting treatment is consistent with the UK GAAP Framework, specifically FRS 102 Section 24, which permits government grants and equivalent credits to be recognised as other income where conditions are met.
What does an above-the-line credit look like in practice?
A profitable engineering company with £1,000,000 of qualifying R&D expenditure in its year ended 31 March 2025 recognises a 20% above-the-line credit of £200,000 as other operating income. Corporation tax at 25% is charged on the credit, leaving a net post-tax cash benefit of £150,000, or 15p per £1 of qualifying spend. Use the free eligibility calculator to model the net cash benefit for your own qualifying spend.
How is the 20% credit applied, step by step?
The above-the-line credit does not simply cancel tax automatically. It flows through a statutory sequence of steps set out in the Corporation Tax Act 2009 (as amended for the merged scheme by Finance (No.2) Act 2023). Understanding this sequence matters for cash-flow forecasting and loan covenant management.
- Calculate the gross credit. The credit equals 20% of qualifying R&D expenditure for the accounting period (27% under ERIS for qualifying loss-making companies). This is the starting figure before any offset or tax charge.
- Recognise the credit as taxable income. The gross credit is included in taxable profits for the period. Corporation tax at the prevailing rate (25% for most companies from April 2023) is charged on it. For a profitable company paying 25% CT, this immediately reduces the net economic benefit from 20p to 15p per £1 of qualifying spend.
- Set against current-period CT liability. The gross credit is first applied to discharge the company's corporation tax liability for the same accounting period. For most profitable companies, this is the primary and only step needed.
- Set against outstanding CT from prior periods. Any credit remaining after Step 3 is applied against corporation tax unpaid from earlier periods, or any other HMRC tax debts of the company that are overdue.
- Group surrender. Where the company is part of a corporate group, any credit not consumed in Steps 3 and 4 may be surrendered to a fellow group company to discharge that company's CT liability. This step is optional and must be actively elected.
- Set against PAYE, NIC, and CIS liabilities. Any remaining credit is applied to discharge the company's outstanding obligations for PAYE, employer's National Insurance Contributions, Construction Industry Scheme deductions, and student loan repayments. This step, together with Step 7, is subject to the PAYE/NIC cap described below.
- Cash payment from HMRC. Any credit remaining after all preceding steps is paid to the company in cash by HMRC. This cash payment is also subject to the PAYE/NIC cap. Amounts exceeding the cap in a given period are carried forward to the next accounting period.
What is the PAYE/NIC cap on the payable element?
Steps 6 and 7 above are together subject to a cap based on the company's payroll-related HMRC payments. The cap was introduced to prevent the payable element of the credit from exceeding a reasonable multiple of the company's UK employment footprint, acting as a check on structures that claim large credits against minimal UK employment costs.
The cap formula is: £20,000 plus three times the total PAYE, employer's NIC, CIS deductions, and student loan repayments made by the company to HMRC for the period.
Worked Example: PAYE/NIC cap in practice
A loss-making software company has qualifying R&D expenditure of £600,000 for the year to 31 March 2026. It has no corporation tax liability or arrears, and is not part of a group. The full £120,000 gross credit (20% × £600,000) therefore moves directly to Steps 6 and 7.
The company's PAYE, employer's NIC, CIS deductions, and student loan repayments to HMRC for the period total £30,000.
PAYE/NIC cap: £20,000 + (3 × £30,000) = £110,000.
The amount payable as cash is capped at £110,000. The remaining £10,000 is carried forward to the following accounting period, where it is subject to the same offset steps again.
Cash received from HMRC in the current period: £110,000 (18.3p per £1 of qualifying spend in this period).
Companies whose payable credit is consistently at or near the cap should review their payroll structure. An R&D programme relying heavily on subcontracted or offshore labour, with limited directly employed UK headcount, will produce a low payroll base and therefore a low cap. Carried-forward credit is not lost but defers the cash receipt to a future period when payroll may be higher or CT liability has arisen.
What are the accounting entries for an above-the-line credit?
The double-entry treatment for an above-the-line R&D credit under UK GAAP (FRS 102 Section 24) follows the government grant model. The precise entries depend on whether the credit generates a cash receipt from HMRC, a reduction in CT payable, or both.
Recognising the gross credit:
Dr R&D expenditure credit receivable (balance sheet - other debtors)
Cr Other operating income (profit and loss account)
This entry records the gross credit as income and establishes the receivable against HMRC. It is made when the qualifying expenditure has been incurred and the credit is sufficiently certain to be received.
Where the credit discharges a CT liability:
Dr Corporation tax payable (balance sheet)
Cr R&D expenditure credit receivable (balance sheet)
This entry extinguishes the CT payable and reduces the receivable to the extent the credit offsets CT owed. The corporation tax charge in the profit and loss account is presented gross; the credit is shown separately as other operating income. This separation is the defining feature of the above-the-line presentation: the P&L shows both the gross credit as income and the full CT charge as a tax cost, rather than netting one against the other.
Where the excess credit results in a cash receipt from HMRC:
Dr Bank
Cr R&D expenditure credit receivable (balance sheet)
Why does the above-the-line presentation matter to EBITDA, investors and lenders?
| Profit & loss line | £ |
|---|---|
| Revenue | 2,000,000 |
| Cost of sales | (1,200,000) |
| Gross profit | 800,000 |
| Operating expenses (including R&D) | (650,000) |
| Other income - above-the-line R&D credit | 100,000 |
| Operating profit / EBIT | 250,000 |
Illustrative figures. Because the credit sits above the operating-profit line, it improves EBITDA - which matters for loan covenants, EV/EBITDA valuations and divisional performance reporting.
The term "above the line" describes the position of the credit in the profit and loss account. Because the credit is recognised as other operating income, it flows into earnings before interest and tax (EBIT) and, by extension, into earnings before interest, tax, depreciation and amortisation (EBITDA). This has practical implications beyond accounting presentation.
Loan covenants. Term loans and revolving credit facilities typically contain financial maintenance covenants expressed as EBITDA ratios, such as minimum interest cover (EBITDA : net finance costs) or maximum leverage (net debt : EBITDA). An above-the-line R&D credit increases EBITDA directly, improving headroom under these tests. For a company spending several hundred thousand pounds annually on qualifying R&D, the credit can represent a material share of reported EBITDA. Finance directors preparing covenant compliance certificates should confirm with their adviser that the credit is correctly included in the EBITDA calculation, and verify that the facility agreement's definition of EBITDA does not exclude government grants or equivalent credits.
Investor valuation. Private equity and trade buyers frequently apply an EV/EBITDA multiple as a headline valuation metric. Because the above-the-line credit improves EBITDA, it can reduce the implied entry multiple and make the business appear more attractively valued on a comparable basis. It also ensures the credit is visible to divisional managers and R&D directors in segment reporting, rather than vanishing into the consolidated tax note.
Management P&Ls. Under the old SME enhanced deduction, the R&D benefit did not appear in divisional management accounts at all: it reduced taxable profit at the legal entity level in the annual tax computation, invisible to the business unit. The above-the-line presentation allows an R&D director to include the credit as a line item in their budget and business case, making the economics of continued R&D investment directly visible to those responsible for the programme.
How does an above-the-line credit differ from a below-the-line relief?
UK corporate R&D reliefs have historically been delivered through two distinct mechanisms: above-the-line credits (income recognised in the operating P&L, improving EBIT and EBITDA) and below-the-line reliefs (enhanced deductions that reduce taxable profit but appear only in the corporation tax line).
The old SME enhanced deduction, which applied to accounting periods before 1 April 2024, was a below-the-line relief. Companies claimed an additional deduction of 130% on qualifying expenditure (the rate varied over time), which increased the tax-deductible cost of R&D but did not create any recognisable income in the P&L. The economic benefit appeared only as a reduction in the corporation tax charge, below the operating profit and EBITDA lines. For any reader of the management accounts, or any investor analysing EBITDA, the relief was invisible.
The old large company scheme (the predecessor to RDEC, abolished from 1 April 2016) operated similarly, providing a 130% enhanced deduction on qualifying spend with no above-the-line income recognition.
Under the merged scheme in force from 1 April 2024, all companies use the above-the-line credit mechanism. The Enhanced R&D Intensive Support scheme (ERIS), which provides a 27% credit rate for qualifying loss-making companies with R&D intensity of at least 30%, also operates as an above-the-line credit. ERIS is not a below-the-line relief.
Why was the above-the-line mechanism introduced?
The Research and Development Expenditure Credit was introduced by the Finance Act 2013 and made available as an optional route for large companies for accounting periods beginning on or after 1 April 2013. It became the sole route for large companies when the old large company scheme was abolished from 1 April 2016.
Before RDEC, large companies claimed under the large company scheme, which provided a 130% enhanced deduction on qualifying R&D expenditure. The benefit was below the line: it reduced taxable profit and appeared only in the consolidated tax computation, not in the trading P&L. The consequence was that R&D directors and divisional managers had no direct sight of the relief. A business case for a multi-year R&D programme could not include the tax benefit as an explicit P&L item because the credit flowed entirely through a central group tax function.
The above-the-line mechanism was a deliberate policy response to this. By presenting the credit as income in the operating P&L, HMRC and HM Treasury intended to make R&D investment decisions more commercially visible at divisional level. An R&D director could include the 20% credit as an explicit line in their budget, improving the apparent rate of return on R&D investment and making the case for continued spend to a board or investment committee.
From 1 April 2024, the merged scheme extended this same above-the-line mechanism to all companies, completing the transition from the below-the-line model that characterised UK R&D relief until 2013. For the latest HMRC-sourced figures on total R&D relief claimed under the merged scheme, see the R&D tax credit statistics page.
What happens when the credit exceeds the corporation tax liability?
A company whose gross R&D credit is larger than its corporation tax liability for the period will exhaust Step 3 without fully using the credit. The balance flows through Steps 4 to 7, ultimately producing a cash payment from HMRC. The following example illustrates the full offset sequence for a nearly break-even company.
Worked Example: credit exceeds CT liability
A manufacturing company has the following position for the year ended 31 March 2026.
Trading loss before recognising R&D credit: £80,000. Qualifying R&D expenditure (staffing and materials): £500,000. Gross credit at 20%: £100,000.
P&L after credit: Trading loss £(80,000), add other operating income (R&D credit) £100,000 = profit before tax of £20,000. Corporation tax at 25%: £5,000.
Credit offset (Steps 3 and 4): £5,000 of the gross credit is set against the £5,000 CT liability, reducing CT to nil. Remaining credit after Step 3: £95,000. The company has no CT arrears, so Step 4 is not needed.
Group surrender (Step 5): Not applicable. The company is standalone.
PAYE/NIC cap (Steps 6 and 7): PAYE, employer NIC, CIS, and student loan repayments for the period total £45,000. Cap = £20,000 + (3 × £45,000) = £155,000. The remaining £95,000 is comfortably within the cap.
Cash received from HMRC: £95,000 (Steps 6 and 7 combined).
Total benefit in the period: CT reduced to nil (a £5,000 saving) plus £95,000 cash = £100,000, equal to the full gross credit. The effective net benefit here is 20p per £1 of qualifying spend, higher than the 15p rate for a profitable company, because the company's taxable profit (after including the credit as income) was small and the associated CT charge was modest relative to the credit.
Where the remaining credit after Step 4 exceeds the PAYE/NIC cap, the excess is not forfeited. It is carried forward to the next accounting period and subject to the same offset sequence. Companies with a sustained excess should model the carry-forward position alongside expected future CT liabilities and payroll growth, as the release of the carry-forward depends on both.
How do FRS 102 and IFRS differ in accounting for the credit?
The above-the-line presentation described throughout this page reflects the treatment under FRS 102, the most common financial reporting framework for UK private companies. Companies reporting under IFRS as adopted in the UK face a different set of choices that can affect where the credit appears in the P&L.
FRS 102 (Section 24 - Government Grants). FRS 102 treats R&D expenditure credits as government grants. Section 24 requires a grant to be recognised as income when conditions attaching to it are sufficiently certain to be met. For the above-the-line R&D credit, recognition occurs when qualifying expenditure has been incurred and there is no significant uncertainty about the claim. The credit appears as other operating income, above the tax line. This is the treatment anticipated by HMRC guidance and the presentation that produces the EBITDA and covenant benefits described earlier in this page.
IFRS (IAS 20 - Accounting for Government Grants, income approach). Under IAS 20, a government grant may be recognised as income when there is reasonable assurance that the company will comply with the conditions and the grant will be received. Applied to R&D credits, this produces an above-the-line result broadly equivalent to FRS 102: the credit appears as other income and improves EBITDA. Most IFRS preparers adopt this approach.
IFRS (IAS 12 - Income Taxes, alternative treatment). A minority of IFRS companies apply IAS 12 rather than IAS 20, on the basis that the credit is more analogous to a tax credit than to a government grant. Under IAS 12, the credit reduces the current tax charge rather than appearing as income. This places the benefit below the operating profit line, in the tax section of the P&L. The economic value is identical, but the EBITDA impact is nil. For companies with covenant or valuation sensitivity to EBITDA, the accounting policy choice between IAS 20 and IAS 12 is therefore material.
Related terms
Frequently asked questions
An above-the-line credit is R&D tax relief recognised as taxable income in a company's profit and loss account, above the operating-profit line, rather than as a reduction in the corporation tax charge. From 1 April 2024 the UK's merged R&D scheme delivers all R&D relief this way, at 20% of qualifying expenditure (27% under ERIS).
For a profitable company paying corporation tax at 25%, a 20% gross credit is reduced to a net cash benefit of around 15p for every £1 of qualifying R&D expenditure, because corporation tax is charged on the gross credit before the net amount is retained or paid out.
Yes. Because the credit is recognised as other operating income rather than as a reduction in the tax line, it sits above the operating-profit line and increases reported EBIT and EBITDA, which can affect loan covenant headroom and EV/EBITDA valuation multiples.
The payable element of the credit, after it has been set against corporation tax and any group surrender, is capped at £20,000 plus three times the company's PAYE, employer's National Insurance, CIS deductions and student loan repayments for the period. Amounts above the cap are carried forward to the next accounting period.
The former SME enhanced deduction was a below-the-line relief: it reduced taxable profit but never appeared as income in the profit and loss account, so it had no effect on EBIT or EBITDA. The above-the-line credit used by the merged scheme is recognised as income first, which makes the relief visible in headline profit measures.